If you’re wondering what your symptoms may mean, you can take the ADAM questionnaire. It was developed by a physician and is used extensively by healthcare providers to help identify men who may have low testosterone. Remember, only your healthcare provider can determine if your symptoms really add up to Low T.
In order to confirm that you have Low T, your doctor will perform a blood test to determine if your testosterone levels are within an acceptable range.
Important Safety Information: Testim® is a prescription medicine used to treat hypogonadism, a medical condition that occurs when the body does not make enough testosterone. Only your doctor can decide if Testim is right for you. Testim should not be used by men with known or suspected cancer of the prostate or breast. Testim has not been approved or evaluated for use in women, and must not be used by women. Testosterone may cause fetal harm. Pregnant and nursing women, as well as children, should avoid skin contact with Testim application sites in men. In controlled clinical studies of Testim, the most common side effects reported were redness/irritation at the application site (4%) and above normal red blood cell count (2%).
Indication: Testim® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Important Safety Information: Androgens are contraindicated in men with cancer known or suspected of the breast or prostate. Testim is not indicated for use in women, has not been evaluated for use in women, and must not be used in women. Testosterone may cause fetal harm. Pregnant and nursing women, as well as children, should avoid skin contact with Testim application sites. Geriatric patients treated with androgens may be at greater risk of prostatic hyperplasia and prostatic carcinoma.
Adverse Events: Adverse events reported at a level greater than 1% that were possibly or definitely related to the use of Testim in controlled clinical trials (N=304) across all dose groups were application site reaction (4%) and increase in hematocrit/hemoglobin (2%).